The Fly | FTRE

Established Client Base and Relationships: Inherited a significant portfolio of active clinical trials and long-standing relationships with pharmaceutical and biotech companies from its spin-off from Labcorp.

Experienced Workforce and Leadership: Retained a highly skilled and experienced workforce, including scientific, operational, and leadership teams, ensuring continuity and deep expertise in clinical research.

Comprehensive Clinical Trial Services: Offers an end-to-end suite of services across all phases of clinical development, including patient access, clinical operations, data management, biostatistics, and regulatory affairs, providing integrated solutions to clients.

Limited Standalone Operating History: Fortrea's recent spin-off means it has a limited track record as an independent public company, which could impact investor confidence and operational stability.

Intense Market Competition: The contract research organization market is highly competitive, with established players vying for client contracts, potentially impacting pricing, margins, and market share.

Reliance on Biopharma R&D Spending: Fortrea's revenue is heavily dependent on the research and development budgets of pharmaceutical and biotechnology companies, which can fluctuate due to economic conditions, funding availability, and pipeline success.

Charts

Limited Standalone Operating History: Fortrea's recent spin-off means it has a limited track record as an independent public company, which could impact investor confidence and operational stability.